Introduction {#Sec1}
============

In patients with end-stage chronic kidney disease (CKD) requiring dialysis, cardiovascular mortality is 5 times higher than in the general population \[[@CR1]\]. Furthermore, studies have demonstrated that even early stages of CKD, which are more prevalent than end-stage CKD requiring dialysis \[[@CR2]\], are associated with elevated risk of cardiovascular disease and mortality \[[@CR3], [@CR4]\]. Therefore, accurate detection of cardiovascular disease in patients with early stages of CKD is important for accurate risk stratification.

The coronary calcium score (CCS) measured by computed tomography can predict the presence of significant coronary artery disease (CAD) in the general population \[[@CR5]--[@CR10]\]. While end-stage CKD is associated with elevated CCS as compared with the general population, several reports have demonstrated conflicting results in the correlation between CCS and the presence of significant CAD \[[@CR10]--[@CR13]\]. Moreover, the role of CCS to detect CAD in patients with moderate CKD, who are at risk for future cardiovascular events, is unknown. Therefore the aim of the current study was to evaluate the predictive role of CCS for diagnosing CAD by computed tomography coronary angiography (CTA) in patients with moderate CKD compared with patients without significant CKD.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The study population consisted of 704 patients who underwent CCS and CTA assessment for suspected CAD. Patients were enrolled at the Leiden University Medical Center. Exclusion criteria included cardiac arrhythmias, severe renal insufficiency (defined as an eGFR \<30 mL/min/m^2^), known hypersensitivity to iodine contrast media and pregnancy.

Classification of moderate chronic kidney disease {#Sec4}
-------------------------------------------------

Serum creatinine levels were used to assess the eGFR calculated with the Modified Diet in Renal Disease equation \[[@CR14]\]. In order to prevent contrast-induced renal dysfunction affecting the analysis, only serum creatinine levels obtained prior to the CTA examination (up to 180 days prior to CTA) were used. Of note, patients with suspected acute renal failure (defined by an increase in serum creatinine of ≥0.5 mg/dl in \<2 weeks or an increase of \>20 % over baseline if baseline serum creatinine was ≥2.5 mg/dl) were excluded.

Patients were stratified into those with moderate CKD and those without significant CKD. The definition of moderate CKD was based on the recommendation from the National Kidney Foundation \[[@CR15]\] using a value of eGFR between 30 and 59 mL/min/1.73m^2^. Patients with eGFR ≥60 mL/min/1.73m^2^ were considered to have no significant CKD. The mean duration between renal function assessment and CTA was 37 ± 14 days.

Computed tomography coronary angiography protocol {#Sec5}
-------------------------------------------------

Examinations of CCS and CTA were performed using a 64-row (Aquillion64, Toshiba Medical Systems, Tokyo Japan) computed tomography scanner. Descriptions of scan parameters for CCS and CTA assessment have been published previously \[[@CR16], [@CR17]\].

Data analysis {#Sec6}
-------------

Post-processing of the CCS and CTA was performed on dedicated workstations (Vitrea2, Vital Images, Minneapolis, Minnesota, USA). The CCS was calculated using the Agatston method and patients were stratified as CCS 0, CCS 1 to 399 and CCS ≥ 400. Coronary anatomy was assessed in a standardised method by dividing the coronary arteries into 17 segments \[[@CR18]\]. All CTA were interpreted by two experienced cardiologists blinded to the results of the CCS and eGFR. Classification of CTA results was made between non-obstructive and obstructive CAD using a luminal narrowing ≥50 % as a threshold for obstructive CAD lesions. In addition, the number of segments (among the 17 segments) and vessels (among the 3 coronaries) involved in each category of CAD (presence of CAD, non-obstructive CAD and obstructive CAD) was measured.

Statistical analysis {#Sec7}
--------------------

Continuous variables are presented as mean ± standard deviation and compared using either Student's t or Wilcoxon's rank-sum test as appropriate. Categorical data are presented as frequencies and percentages and compared using the chi-square or Fisher's exact test. Receiver-operator characteristic (ROC) curve analysis was performed to determine the value of CCS in diagnosing obstructive CAD. The optimal cut-off value was defined as the maximised value for the sum of sensitivity and specificity. In addition, the CCS values to diagnose obstructive CAD for a predefined 1) sensitivity of 80 % and 2) specificity of 80 % in patients with moderate CKD and without significant CKD were evaluated. All statistical analyses were performed using the statistical package SPSS for Windows (Version 15.0, SPSS, Chicago, USA). A p value \<0.05 was considered to be statistically significant.

Results {#Sec8}
=======

Baseline clinical characteristics {#Sec9}
---------------------------------

Baseline characteristics of the patient population (704 patients who underwent CCS and CTA) are shown in Table [1](#Tab1){ref-type="table"}. The average age of all patients was 56 ± 12 years and 55 % of patients were male. The mean eGFR for all patients was 84.7 ± 21.5 mL/min/1.73m^2^. Patients with moderate CKD were more likely to be older, obese and to have a history of hypertension while patients without significant CKD were more likely to be a smoker.Table 1Baseline demographics on all patients, patients with moderate chronic kidney disease (CKD) and patients without significant CKDAll (*n* = 704)Moderate CKD (*n* = 69)No significant CKD (*n* = 635)*p* valueAge (years)56 ± 1262 ± 1255 ± 12\<0.01Male gender (%)385 (54.7)39 (56.5)346 (54.5)0.80Risk factors (%)- Diabetes245 (34.8)27 (39.1)218 (34.3)0.43- Hypertension329 (46.7)43 (62.3)286 (45)\<0.01- Hypercholesterolaemia281 (39.9)35 (50.7)246 (38.7)0.07- Family history of CAD331 (44.2)26 (37.7)285 (44.9)0.31- Smoking149 (21.2)7 (10.1)142 (22.4)0.02- Obesity BMI \>30 kg/m^2^150 (21.3)24 (34.8)126 (19.8)\<0.01Previous MI (%)41 (5.8)4 (5.8)37 (5.8)1.00Previous PCI (%)44 (6.2)4 (5.8)40 (6.3)1.00*BMI* body mass index; *CAD* coronary artery disease; *MI* myocardial infarction; *PCI* percutaneous coronary intervention

Coronary calcium score {#Sec10}
----------------------

The mean and median CCS of the whole population was 274 and19 respectively. Coronary calcium was absent in 36 % patients, a CCS of 1 to 399 was present in 46 % patients and CCS ≥ 400 in 18 % patients. The mean and median CCS of patients with moderate CKD were higher than in patients without significant CKD. Moreover, patients with moderate CKD had a higher prevalence of CCS 1--399 and CCS ≥ 400 than patients without significant CKD (Table [2](#Tab2){ref-type="table"}).Table 2Coronary calcium score (CCS) and computed tomography coronary angiography results in patients with moderate CKD and without significant CKDAll patients (*n* = 704)Moderate CKD (*n* = 69)No significant CKD (*n* = 635)*p* valueMean CCS273 ± 760592 ± 1074265 ± 7120.02Median CCS (Interquatile range)19 (0, 265)129 (22, 746)14 (0, 216)- CCS 0 (%)255 (36.2)11 (15.9)244 (38.4)0.01- CCS 1--399 (%)320 (45.5)36 (52.2)284 (44.7)- CCS \> 400 (%)129 (18.3)22 (31.9)107 (16.9)Presence of CAD (%)451 (64.1)56 (81.2)395 (62.2)\<0.01- Number of segments3.5 ± 3.84.8 ± 4.03.3 ± 3.8\<0.01- Number of vessels1.7 ± 1.32.3 ± 1.11.7 ± 1.3\<0.01Presence of non-obstructive CAD (%)232 (33.0)30 (43.5)202 (31.8)0.059- Number of segments2.8 ± 3.13.9 ± 3.42.6 ± 3.1\<0.01- Number of vessels1.7 ± 1.32.2 ± 1.11.6 ± 1.3\<0.01Presence of obstructive CAD (%)219 (31.1)26 (37.7)193 (30.4)0.22- Number of segments0.7 ± 1.41.0 ± 1.70.7 ± 1.40.20- Number of vessels0.5 ± 0.90.6 ± 0.90.5 ± 0.90.28Abbreviations as for Table [1](#Tab1){ref-type="table"}

Computed tomography coronary angiography results {#Sec11}
------------------------------------------------

Presence of CAD was detected in 64 % of patients including non-obstructive CAD in 33 % and obstructive CAD in 31 % of patients. Patients with moderate CKD had a higher prevalence of CAD, increased number of segments and vessels with CAD as compared with patients without significant CKD (Table [2](#Tab2){ref-type="table"}). In addition, patients with moderate CKD had a higher prevalence of non-obstructive CAD although this observation did not reach statistical significance (*p* = 0.059). Nevertheless, the number of segments and vessels involved with non-obstructive CAD was higher in patients with moderate CKD. In contrast, the prevalence of obstructive CAD and the number of segments and vessels with obstructive CAD was similar between patients with moderate CKD and those without significant CKD.

CTA results in relation to coronary calcium score {#Sec12}
-------------------------------------------------

The results of CTA in relation to CCS subgroups in patients with moderate CKD and patients without significant CKD are shown in Table [3](#Tab3){ref-type="table"}. Among the two groups of patients with moderate CKD and patients without significant CKD, the prevalence of the presence of CAD, non-obstructive CAD and obstructive CAD was significantly higher in subgroups of patients with a higher CCS. Moreover, the number of segments and vessels involved with the presence of CAD, non-obstructive CAD and obstructive CAD increased in subgroups of patients with higher CCS.Table 3Results of computed tomography coronary angiography according to CCS subgroups in patients with moderate CKD and without significant CADCCS = 0CCS 1--399CCS ≥ 400*p* valueModerate CKDPresence of CAD (%)2 (18.2)32 (88.9)22 (100)\<0.01- Number of segments0.4 ± 0.93.6 ± 2.99.1 ± 2.6\<0.01- Number of vessels0.4 ± 0.72.5 ± 0.83.0 ± 0.2\<0.01Presence of non-obstructive CAD (%)1 (9.1)22 (61.1)7 (31.8)\<0.01- Number of segments0.2 ± 0.43.1 ± 2.67.0 ± 2.9\<0.01- Number of vessels0.3 ± 0.52.4 ± 0.82.9 ± 0.4\<0.01Presence of obstructive CAD (%)1 (9.1)10 (27.8)15 (68.2)\<0.01- Number of segments0.2 ± 0.60.5 ± 1.12.1 ± 2.3\<0.01- Number of vessels0.1 ± 0.31.3 ± 1.11.3 ± 1.1\<0.01Without significant CADPresence of CAD (%)54 (22.1)235 (82.7)106 (99.1)\<0.01- Number of segments0.6 ± 1.43.7 ± 3.18.7 ± 3.1\<0.01- Number of vessels0.5 ± 1.02.2 ± 1.02.9 ± 0.3\<0.01Presence of non-obstructive CAD (%)37 (15.2)137 (8.2)28(26.2)\<0.01- Number of segments0.5 ± 1.23.0 ± 2.66.5 ± 2.9\<0.01- Number of vessels0.5 ± 0.92.1 ± 1.02.8 ± 0.5\<0.01Presence of obstructive CAD (%)17 (7.0)98 (34.5)78 (72.9)\<0.01- Number of segments0.1 ± 0.40.6 ± 1.22.2 ± 2.2\<0.01- Number of vessels0.1 ± 0.30.5 ± 0.81.4 ± 1.1\<0.01Abbreviations as for Table [1](#Tab1){ref-type="table"}

Prediction of obstructive coronary artery disease {#Sec13}
-------------------------------------------------

To evaluate the predictive value of CCS for diagnosing obstructive CAD in patients with moderate CKD and patients without significant CKD, ROC curve analysis was performed. As shown in Fig. [1](#Fig1){ref-type="fig"}, CCS predicted the presence of obstructive CAD in both patients with moderate CKD (area under curve 0.78, *p* \< 0.01) and patients without significant CKD (area under curve 0.82, *p* \< 0.01). The individual sensitivity and specificity of CCS to predict obstructive CAD in patients with moderate CKD and patients without significant CKD are shown in Fig. [2](#Fig2){ref-type="fig"}. In patients with moderate CKD, the optimal cut-off value of CCS to diagnose obstructive CAD was 140 (sensitivity 73 % and specificity of 70 %). On the other hand, the optimal cut-off value of CCS for patients without significant CKD to diagnose obstructive CAD was 50 (sensitivity 75 % and specificity 75 %). To achieve a predefined sensitivity of 80 % for diagnosing obstructive CAD, the required value of CCS in patients with moderate CKD was higher than in patients without significant CKD (110 vs. 27, corresponding specificity 60 % vs. 70 % respectively). Similarly, a higher CCS was required to achieve a predefined specificity of 80 % for diagnosing obstructive CAD in patients with moderate CKD than in patients without significant CKD (345 vs. 90, corresponding sensitivity 62 % vs. 71 % respectively).Fig. 1Receiver-operator characteristics curve analysis of patients with moderate chronic kidney disease (CKD) (Panel **a**) and without significant CKD (Panel **b**). The optimal cut-off value of the coronary calcium score (CCS) to diagnose obstructive coronary artery disease (CAD) in patients with moderate CKD is 140 (sensitivity 73 % and specificity 70 %). The optimal cut-off value of CCS to diagnose obstructive CAD in patients without significant CKD is 50 (sensitivity 75 % and specificity 75 %)Fig. 2Sensitivity (*dotted lines*) and specificity (*solid lines*) of coronary calcium score (CCS) to predict CAD in patients with moderate CKD (*blue lines*) and patients without significant CKD (*red lines*). The value of CCS is higher in patients with moderate CKD than in patients without significant CKD for a given sensitivity and specificity. Example: a predefined sensitivity and specificity of 80 % (*black lines*) would require a higher CCS in patients with moderate CKD than patients without significant CKD (110 vs. 27 and 345 vs. 90, respectively)

Discussion {#Sec14}
==========

The present report demonstrates that patients with moderate CKD had a higher prevalence, more diffuse and greater extent of coronary calcium and CAD than patients without significant CKD. Moreover, CCS predicted the presence of obstructive CAD in both patients with moderate CKD and patients without significant CKD. Importantly, the optimal cut-off value of CCS for predicting the presence of obstructive CAD was higher in patients with moderate CKD than patients without significant CKD.

Recent studies using computed tomography demonstrated that patients with early stages of CKD had a higher prevalence of CCS and CAD than patients without CKD \[[@CR19], [@CR20]\]. This is in concordance with the present results, demonstrating a higher prevalence, more diffuse and greater extent of coronary calcium and CAD in patients with moderate CKD than patients without significant CKD. Accordingly, these results provided further supporting evidence for the relationship between elevated cardiovascular risk and moderate CKD \[[@CR3], [@CR4]\]. Interestingly, the increased prevalence of CAD in patients with moderate CKD was mainly contributed by the presence of non-obstructive CAD. The observation may partially be explained by the thickening and calcification in the media layer, instead of the intima layer, of the coronaries in patients with moderate CKD, a phenomenon that is classically described as Mönckeberg's calcification or medial calcinosis \[[@CR21], [@CR22]\]. Therefore, in patients with moderate CKD, the elevated CCS located in the medial layer may be associated with non-obstructive coronary atherosclerosis, rather than significant luminal obstruction \[[@CR23]\].

Although the coronary calcification and degree of CAD differed between patients with and without CKD, a close relation between CCS and presence of obstructive CAD has been shown in the general population \[[@CR24], [@CR25]\] as well as in patients with end-stage CKD \[[@CR10]--[@CR12]\]. The present results further showed that high CCS was associated with higher prevalence, more diffuse and greater extent of CAD in both patients with moderate CKD and patients without significant CKD.

In addition to the significant relation with CAD, previous reports have demonstrated that the use of CCS can predict the presence of obstructive CAD in the general population \[[@CR6], [@CR7]\]. Moreover, few studies have evaluated the predictive role of CCS for obstructive CAD in patients with end-stage CKD. In the report by Sharples evaluating 18 patients with CKD requiring dialysis, the presence of CCS was not correlated with obstructive CAD diagnosed by coronary angiogram \[[@CR13]\]. Conversely, Fujimoto et al. demonstrated a CCS value of 1000 provided a sensitivity of 68 % and specificity of 69 % to diagnose obstructive CAD in 76 patients with CKD requiring dialysis \[[@CR10]\]. In addition, Robinson and colleagues showed a CCS value of 400 provided a sensitivity of 86 % and specificity of 83 % in diagnosing obstructive CAD in 37 patients with CKD (17 of them requiring dialysis) \[[@CR12]\]. While these studies mainly evaluated patients with end-stage CKD, none of them explored the role of CCS to predict obstructive CAD specifically in patients with moderate CKD, which is more common in the general population \[[@CR2]\]. Nonetheless, patients with moderate CKD have a greater cardiovascular risk than the general population, highlighting the need for appropriate strategies to detect obstructive CAD \[[@CR3], [@CR4]\]. The results of the present study have thus confirmed the predictive role of CCS in diagnosing obstructive CAD in patients with moderate CKD. However, the optimal cut-off value of CCS was 2.8 fold higher in patients with moderate CKD than patients without significant CKD. For the same sensitivity and specificity to diagnose obstructive CAD, the value of CCS was consistently higher in patients with moderate CKD than patients without significant CKD (Fig. [2](#Fig2){ref-type="fig"}). The reason for this observation has not been fully elucidated, but may possibly be explained by the different morphology and distribution of coronary calcification in patients with and without CKD. Patients with CKD appear to have more diffuse calcified plaque burden that tends to be located in the media wall rather than protruding into the lumen \[[@CR26]\]. Therefore, while the relation between elevated CCS and obstructive CAD existed in patients with moderate CKD, the degree of this relationship is different as compared with patients without moderate CKD. Accordingly, the optimal cut-off value of CCS to predict the presence of obstructive CAD should be different in patients with moderate CKD as compared with patients without significant CKD. However, the exact value of CCS for this purpose requires further evaluation based on larger study populations.

Limitation {#Sec15}
==========

The present study consisted of patients with moderate CKD and the predictive role of CCS to diagnose obstructive CAD in patients with severe CKD (eGFR \< 30 mL/min/1.73m^2^) cannot be extrapolated. Similar to previous evaluations exploring the CTA results of patients with and without CKD, the present study confirmed that patients with moderate CKD were older as compared with patients without significant CKD \[[@CR17]\]. However, due to the small population, the independent association between moderate CKD and high CCS/significant CAD could not be evaluated. Although CCS is proven to be a valuable tool to detect coronary calcification, it is unable to differentiate media calcification, which is common in patients with CKD, from intima calcification. Moreover, whether the use of computed tomography fractional flow reserve will provide additional diagnostic information in patients with CKD would require further studies \[[@CR27]\].

Conclusion {#Sec16}
==========

The present study demonstrates that CCS predicted the presence of obstructive CAD in both patients with moderate CKD and those without significant CKD. More importantly, the optimal cut-off value and the value of CCS for the same sensitivity and specificity to diagnose obstructive CAD were higher in patients with moderate CKD than patients without significant CKD. Therefore in the clinical setting, a higher cut-off value of CCS to predict the presence of obstructive CAD is required in patients with moderate CKD as compared with patients without significant CKD.

Funding {#d30e1394}
=======

Kai Hang Yiu is financially supported by a research grant from the Hong Kong Heart Foundation.

Fleur R. de Graaf was supported by the Dutch Technology Foundation STW (Utrecht, the Netherlands).

The Department of Cardiology of Leiden Univerisity Medical Center (The Netherlands) receives grants from Biotronik, BMS medical imaging, Boston Scientific, Edwards Lifesciences, GE Healthcare, Medtronic and St. Jude Medical.

JW Jukema receives research grants from and was a speaker at meetings sponsored by Astellas, AstraZeneca, Biotronic, Boston Scientific, Bristol-Myers Squibb, Cordis, Daiichi Sankyo, Eli Lilly and Company, Medtronic, Merck-Schering Plough, Pfizer, Orbus Neich, Novartis, Roche, Servier, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands and the European Community Framework KP7 program.

The remaining authors: none.

Conflict of interests {#d30e1407}
=====================

None declared.
